Skip to main content
Clinical Trials/NCT05666843
NCT05666843
Completed
Not Applicable

The Effects of Personalized Dietary Guidance to Increase the Intake of Fibre-rich Foods on Cardiometabolic Risk Profile in Individuals with Type 2 Diabetes. (in Dutch: Voed Je Beter Met Diabetes Type 2)

Wageningen University1 site in 1 country124 target enrollmentNovember 1, 2022

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Diabetes Mellitus, Type 2
Sponsor
Wageningen University
Enrollment
124
Locations
1
Primary Endpoint
Cardiometabolic risk profile (DIAL risk score)
Status
Completed
Last Updated
last year

Overview

Brief Summary

This is a randomized controlled trial to examine whether personalized guidance to increase the consumption of fiber rich food items according to the Dutch dietary guidelines, compared to usual care, improves health of individuals with type 2 diabetes.

Detailed Description

Previous interventions with fibre supplements show promising results among individuals with type 2 diabetes, but wether these effects are similar when higher fiber intake is achieved through diet and not through supplements remains unclear. The primary objective of this study is to investigate the effects of personalized dietary guidance to increase the intake of fibre-rich foods, as recommended in the Dutch dietary guidelines, on cardiometabolic risk profile in individuals who have type 2 diabetes, compared to usual care after six months. The study is a parallel randomized trial over a period of twelve months, including an intervention period of six months and a follow up period of six months. The study population consists of adults with non-insulin-dependent type 2 diabetes, diagnosed by a medical doctor at least 6 months prior to study enrolment.

Registry
clinicaltrials.gov
Start Date
November 1, 2022
End Date
December 31, 2024
Last Updated
last year
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Responsible Party
Principal Investigator
Principal Investigator

Marianne Geleijnse

prof.dr. JM (Marianne) Geleijnse

Wageningen University

Eligibility Criteria

Inclusion Criteria

  • Diagnosis of type 2 diabetes made by a medical doctor at least 6 months prior to study enrolment
  • Willing and able to follow dietary intervention
  • Willing to participate in both intervention and control group
  • Living at a reasonable distance from the research center at Wageningen University \& Research (WUR) (i.e.maximum of ± 1 hour away)

Exclusion Criteria

  • Currently treated with insulin therapy
  • Recently (\< 6 months) or currently being under supervision of a dietician
  • Pregnant or breast-feeding
  • History of bariatric surgery, including gastric banding
  • Current participation in a study with an investigational drug or dietary intervention
  • Excessive alcohol consumption (more than 14 units for males/7 units for females per week) or drug use
  • Clinical disorders that could interfere with the intervention (e.g. gastro-intestinal disorders, auto-immune diseases, psychiatric disorders, uncontrolled heart diseases, serious neurological disorders, renal failure or cancer)
  • Not able to speak and understand the Dutch language
  • No general practitioner
  • Working at the department of Human Nutrition and Health at Wageningen University \& Research

Outcomes

Primary Outcomes

Cardiometabolic risk profile (DIAL risk score)

Time Frame: Change from baseline at 6 months

The change in cardiovascular risk based on observed changes in HbA1c, LDL-cholesterol and systolic blood pressure. DIAL risk score ranges from 0 to 100%, with higher scores indicating a higher risk.

Secondary Outcomes

  • Fasting insulin(baseline, 6 months, 12 month)
  • Leg muscle strength(baseline, 6 months, 12 months)
  • Cardiometabolic risk profile (DIAL risk score)(Change from baseline at 12 months)
  • Liver function(baseline, 6 months, 12 months)
  • Health index score(baseline, 3 months, 6 months, 12 months)
  • Hand grip strength(baseline, 6 months, 12 months)
  • Balance score(baseline, 6 months, 12 months)
  • Skeletal muscle fat infiltration(baseline, 6 months, 12 months)
  • Productivity(baseline, 3 months, 6 months, 12 months)
  • Dietary intake(baseline, 3 months, 6 months, 12 months)
  • Flexibility(baseline, 6 months, 12 months)
  • Body weight (in kilograms)(baseline, 6 months, 12 months)
  • Blood pressure(baseline, 6 months, 12 months)
  • Estimated Glomerular Filtration Rate (eGFR)(baseline, 6 months, 12 months)
  • Urinary albumin levels(baseline, 6 months, 12 months)
  • Inflammatory markers(baseline, 6 months, 12 months)
  • Self efficacy score(baseline, 3 months, 6 months, 12 months)
  • Body mass index (kg/m^2)(baseline, 6 months, 12 months)
  • Blood lipids(baseline, 6 months, 12 months)
  • Micronutrient status(baseline, 6 months, 12 months)
  • Food literacy(baseline, 3 months, 6 months, 12 months)
  • HbA1c(baseline, 6 months, 12 month)
  • Fasting glucose(baseline, 6 months, 12 month)
  • Sleep quality score(baseline, 3 months, 6 months, 12 months)
  • Cardiovascular condition(baseline, 6 months, 12 months)
  • Waist circumference(baseline, 6 months, 12 months)
  • C-peptide(baseline, 6 months, 12 month)
  • Quality of life score(baseline, 3 months, 6 months, 12 months)
  • Positive health score(baseline, 3 months, 6 months, 12 months)
  • Medical consumption(baseline, 3 months, 6 months, 12 months)

Study Sites (1)

Loading locations...

Similar Trials